New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more
(A) Starting with immunized BALB/c mouse splenocytes, the CD138+ cell content of the isolated fraction is typically 81.5 ± 4.9% (mean ± SD). In the above example, the purities of the start and final isolated fractions are 4.6% and 83.3%, respectively.
(B) Starting with immunized BALB/c mouse splenocytes, the plasma cell (CD138+CD267 (TACI)+) content is typically 68.5 ± 11.3% (mean ± SD). In the above example, the purities of the start and final isolated fractions are 1.3% and 70.2%, respectively.
(C) Starting with naïve C57BL/6 mouse splenocytes, the CD138+ cell content of the isolated fraction is typically 78.3 ± 5.7% (mean ± SD). In the above example, the purities of the start and final isolated fractions are 5.0% and 79.5%, respectively.
(D) Starting with naïve C57BL/6 mouse splenocytes, the plasma cell (CD138+CD267 (TACI)+) content is typically 50.8 ± 10.0 % (mean ± SD). In the above example, the purities of the start and final isolated fractions are 0.4% and 56.3%, respectively.
(E) Isolated CD138+ cells or total splenocytes from mice immunized with various antigens were fused with Sp2/0 mouse myeloma cells and plated in semi-solid medium using ClonaCell™-HY Hybridoma Kit (Catalog #03800). The % antigen-specific hit rate was determined by ELISA. The % antigen-specific hit rates for total splenocytes and CD138+ cells were 4.1 ± 1.6% and 28.8 ± 11.0% (mean ± SD), respectively.
(F) Isolated CD138+ cells or total splenocytes from mice immunized with various antigens were fused with Sp2/0 mouse myeloma cells and plated in semi-solid medium using ClonaCell™-HY Hybridoma Kit (Catalog #03800). The % antibody-secreting hybridomas was determined by ELISA. The % antibody-secreting hybridomas for total splenocytes and CD138+ cells were 33.0 ± 8.7% and 99.3 ± 0.6% (mean ± SD), respectively.
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Thank you for your interest in IntestiCult™ Organoid Growth Medium (Human). Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they
can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
By submitting this form, you are providing your consent to STEMCELL Technologies Canada Inc. and its subsidiaries and affiliates (“STEMCELL”) to collect and use your information, and send you newsletters and emails in accordance with our
privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
